Upstream Bio has dosed the first subject in the Phase II trial of verekitug in individuals with chronic obstructive pulmonary disease (COPD).

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

See the full release here. Full Release – Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – ...

Broadens global development program for verekitug into third indication, strengthening pipeline across severe respiratory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP), severe ...

A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – ...

A comprehensive meta-analysis of over 4.3 million adults shows e-cigarette use is associated with significantly higher odds ...

It is becoming increasingly recognized that people with COPD have an elevated risk of serious CV events,1 discussed Hanania ...

A recent population-based study published in the Journal of American Medical Association identified a modest increase in ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.

Digital inhalers may help predict the occurrence of acute exacerbations of chronic obstructive pulmonary disease (COPD) for ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...